Avalo Therapeutics, Inc. (NASDAQ: AVTX) is a Healthcare company (Biotechnology) with a market capitalization of $412M. The Maz Rating grades it against the other companies in its sector.
Avalo Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.13, Avalo Therapeutics, Inc. trades at 6909.4x sales and 0.9x book value. Over the last twelve months it generated about $59670 of revenue and a net loss of $169M. It runs a gross margin of 71.2%, an operating margin of -161961.0% and a net margin of -150259.3%. It shows return on equity of -34.2%, return on invested capital of -20.9% and a free cash flow yield of -15.1%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 16.63. Over the past 52 weeks the share price ranged from $6.53 to $24.27, with a beta of 0.74.
Avalo Therapeutics, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 6 Buy, 3 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Avalo Therapeutics, Inc. (AVTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 75.3% / 30% · Interest income / Revenue 424900000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 64.0% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 424900000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 64.0% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 424900000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.36% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 81.9% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 424900000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 81.6% / 33.33% · (Cash+Recv) / Total Assets 81.6% / 33.33% · Interest income / Revenue 424900000.0% / 5% | Fail |
No. As of September 2026, Avalo Therapeutics, Inc. (AVTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Avalo Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 424900000.0% of each dividend: Avalo Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.